Pembrolizumab
Stage IV Urethral Cancer AJCC v8
Emory Universitymonoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Stage IV Urethral Cancer AJCC v8 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Epirubicin Emory University | Phase 2 | B |
Bms-907351 National Cancer Institute (NCI) | Phase 2 | B |
Cyclophosphamide Emory University | Phase 2 | B |
Nivolumab M.D. Anderson Cancer Center | Phase 2 | B |
Ipilimumab M.D. Anderson Cancer Center | Phase 2 | B |
PROPRANOLOL Emory University | Phase 2 | CCC |
Avelumab Emory University | Phase 2 | CCC |
PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493 National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Pembrolizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →